MedTrace Logo

A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

NCT06379867 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-04-26

No results posted yet for this study

Summary

Assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization for healthy subjects.

Conditions

  • Anesthesia

Interventions

DRUG

HSK3486

0.4 mg/kg, IV bolus administration

DRUG

Placebo

IV bolus administration

DRUG

Moxifloxacin

0.4 g, Oral administration with 240 mL

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-07
Primary Completion
2024-05-30
Completion
2024-08-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379867 on ClinicalTrials.gov